vs
Side-by-side financial comparison of ASCENT INDUSTRIES CO. (ACNT) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $11.9M, roughly 1.4× ASCENT INDUSTRIES CO.). Journey Medical Corp runs the higher net margin — -7.8% vs -8.8%, a 1.0% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 13.3%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs -34.9%).
ASCENT INDUSTRIES CO.ACNTEarnings & Financial Report
Ascent Capital Group, Inc. was a publicly traded holding company whose primary subsidiary was Monitronics. Ascent Media was a wholly owned subsidiary of the Discovery Holding Company (DHC). DHC spun off Ascent Media as an independent, public company on September 17, 2008.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
ACNT vs DERM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.9M | $16.1M |
| Net Profit | $-1.0M | $-1.2M |
| Gross Margin | 14.6% | — |
| Operating Margin | -21.0% | -2.8% |
| Net Margin | -8.8% | -7.8% |
| Revenue YoY | 13.3% | 27.3% |
| Net Profit YoY | -1.2% | -182.0% |
| EPS (diluted) | $-0.11 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.9M | $16.1M | ||
| Q3 25 | $19.7M | $17.0M | ||
| Q2 25 | $18.7M | $15.0M | ||
| Q1 25 | $24.7M | $13.1M | ||
| Q4 24 | $10.5M | $12.6M | ||
| Q3 24 | $20.9M | $14.6M | ||
| Q2 24 | $21.5M | $14.9M | ||
| Q1 24 | $28.0M | $13.0M |
| Q4 25 | $-1.0M | $-1.2M | ||
| Q3 25 | $-2.1M | $-2.3M | ||
| Q2 25 | $6.3M | $-3.8M | ||
| Q1 25 | $-2.3M | $-4.1M | ||
| Q4 24 | $-1.0M | $1.5M | ||
| Q3 24 | $-6.2M | $-2.4M | ||
| Q2 24 | $-926.0K | $-3.4M | ||
| Q1 24 | $-5.5M | $-10.4M |
| Q4 25 | 14.6% | — | ||
| Q3 25 | 29.7% | — | ||
| Q2 25 | 26.1% | — | ||
| Q1 25 | 19.3% | — | ||
| Q4 24 | 24.3% | 82.3% | ||
| Q3 24 | 14.4% | 63.9% | ||
| Q2 24 | 13.1% | 56.0% | ||
| Q1 24 | 8.3% | 47.7% |
| Q4 25 | -21.0% | -2.8% | ||
| Q3 25 | -4.1% | -9.0% | ||
| Q2 25 | -14.4% | -19.2% | ||
| Q1 25 | -4.2% | -25.3% | ||
| Q4 24 | -25.4% | 17.7% | ||
| Q3 24 | -9.4% | -19.8% | ||
| Q2 24 | -8.6% | -19.7% | ||
| Q1 24 | -15.5% | -77.4% |
| Q4 25 | -8.8% | -7.8% | ||
| Q3 25 | -10.6% | -13.6% | ||
| Q2 25 | 33.7% | -25.3% | ||
| Q1 25 | -9.3% | -31.0% | ||
| Q4 24 | -9.8% | 12.1% | ||
| Q3 24 | -29.5% | -16.3% | ||
| Q2 24 | -4.3% | -22.6% | ||
| Q1 24 | -19.7% | -80.1% |
| Q4 25 | $-0.11 | $-0.04 | ||
| Q3 25 | $-0.22 | $-0.09 | ||
| Q2 25 | $0.65 | $-0.16 | ||
| Q1 25 | $-0.23 | $-0.18 | ||
| Q4 24 | $-0.11 | $0.10 | ||
| Q3 24 | $-0.61 | $-0.12 | ||
| Q2 24 | $-0.09 | $-0.17 | ||
| Q1 24 | $-0.54 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $57.6M | $24.1M |
| Total DebtLower is stronger | — | $25.3M |
| Stockholders' EquityBook value | $87.0M | $31.9M |
| Total Assets | $111.9M | $94.6M |
| Debt / EquityLower = less leverage | — | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $57.6M | $24.1M | ||
| Q3 25 | $58.0M | $24.9M | ||
| Q2 25 | $60.5M | $20.3M | ||
| Q1 25 | $14.3M | $21.1M | ||
| Q4 24 | $16.1M | $20.3M | ||
| Q3 24 | $8.5M | $22.5M | ||
| Q2 24 | $3.6M | $23.9M | ||
| Q1 24 | $1.3M | $24.1M |
| Q4 25 | — | $25.3M | ||
| Q3 25 | — | $25.2M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | $0 | $24.9M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $14.7M |
| Q4 25 | $87.0M | $31.9M | ||
| Q3 25 | $87.1M | $25.9M | ||
| Q2 25 | $89.7M | $19.2M | ||
| Q1 25 | $91.2M | $21.5M | ||
| Q4 24 | $93.5M | $20.1M | ||
| Q3 24 | $94.7M | $10.9M | ||
| Q2 24 | $101.0M | $11.3M | ||
| Q1 24 | $102.0M | $13.0M |
| Q4 25 | $111.9M | $94.6M | ||
| Q3 25 | $119.9M | $85.2M | ||
| Q2 25 | $122.6M | $81.2M | ||
| Q1 25 | $152.5M | $85.0M | ||
| Q4 24 | $147.3M | $80.2M | ||
| Q3 24 | $148.6M | $64.0M | ||
| Q2 24 | $158.2M | $65.2M | ||
| Q1 24 | $161.0M | $66.6M |
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | 0.00× | 1.24× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $266.0K | $-6.3M |
| Free Cash FlowOCF − Capex | $-196.0K | — |
| FCF MarginFCF / Revenue | -1.7% | — |
| Capex IntensityCapex / Revenue | 3.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-2.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $266.0K | $-6.3M | ||
| Q3 25 | $1.3M | $-2.4M | ||
| Q2 25 | $-1.4M | $-942.0K | ||
| Q1 25 | $-700.0K | $-2.8M | ||
| Q4 24 | $8.8M | $2.2M | ||
| Q3 24 | $3.4M | $-1.2M | ||
| Q2 24 | $2.2M | $-5.2M | ||
| Q1 24 | $263.0K | $-5.0M |
| Q4 25 | $-196.0K | — | ||
| Q3 25 | $695.0K | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-1.0M | — | ||
| Q4 24 | $8.4M | — | ||
| Q3 24 | $3.1M | — | ||
| Q2 24 | $1.9M | — | ||
| Q1 24 | $25.0K | — |
| Q4 25 | -1.7% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | -8.3% | — | ||
| Q1 25 | -4.1% | — | ||
| Q4 24 | 80.6% | — | ||
| Q3 24 | 15.1% | — | ||
| Q2 24 | 9.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | 3.9% | — | ||
| Q3 25 | 3.1% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.22× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACNT
| Other | $6.1M | 52% |
| Transferred At Point In Time | $5.7M | 48% |
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
